GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » European Medical Solutions (FRA:AS0) » Definitions » Gross Margin %

European Medical Solutions (FRA:AS0) Gross Margin % : 29.19% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is European Medical Solutions Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. European Medical Solutions's Gross Profit for the six months ended in Dec. 2023 was €5.76 Mil. European Medical Solutions's Revenue for the six months ended in Dec. 2023 was €19.75 Mil. Therefore, European Medical Solutions's Gross Margin % for the quarter that ended in Dec. 2023 was 29.19%.


The historical rank and industry rank for European Medical Solutions's Gross Margin % or its related term are showing as below:

FRA:AS0' s Gross Margin % Range Over the Past 10 Years
Min: 25   Med: 33.27   Max: 34.75
Current: 33.31


During the past 12 years, the highest Gross Margin % of European Medical Solutions was 34.75%. The lowest was 25.00%. And the median was 33.27%.

FRA:AS0's Gross Margin % is ranked worse than
76.23% of 749 companies
in the Biotechnology industry
Industry Median: 60.9 vs FRA:AS0: 33.31

European Medical Solutions had a gross margin of 29.19% for the quarter that ended in Dec. 2023 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for European Medical Solutions was 0.00% per year.


European Medical Solutions Gross Margin % Historical Data

The historical data trend for European Medical Solutions's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Medical Solutions Gross Margin % Chart

European Medical Solutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 33.23 34.75 33.31

European Medical Solutions Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 38.03 31.25 37.22 29.19

Competitive Comparison of European Medical Solutions's Gross Margin %

For the Biotechnology subindustry, European Medical Solutions's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


European Medical Solutions's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, European Medical Solutions's Gross Margin % distribution charts can be found below:

* The bar in red indicates where European Medical Solutions's Gross Margin % falls into.



European Medical Solutions Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

European Medical Solutions's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=13.5 / 40.564
=(Revenue - Cost of Goods Sold) / Revenue
=(40.564 - 27.053) / 40.564
=33.31 %

European Medical Solutions's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=5.8 / 19.748
=(Revenue - Cost of Goods Sold) / Revenue
=(19.748 - 13.984) / 19.748
=29.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


European Medical Solutions  (FRA:AS0) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

European Medical Solutions had a gross margin of 29.19% for the quarter that ended in Dec. 2023 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


European Medical Solutions Gross Margin % Related Terms

Thank you for viewing the detailed overview of European Medical Solutions's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


European Medical Solutions (FRA:AS0) Business Description

Traded in Other Exchanges
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

European Medical Solutions (FRA:AS0) Headlines

No Headlines